983 related articles for article (PubMed ID: 25548472)
1. Intestinal microbiota and type 2 diabetes: from mechanism insights to therapeutic perspective.
Han JL; Lin HL
World J Gastroenterol; 2014 Dec; 20(47):17737-45. PubMed ID: 25548472
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus.
Kootte RS; Vrieze A; Holleman F; Dallinga-Thie GM; Zoetendal EG; de Vos WM; Groen AK; Hoekstra JB; Stroes ES; Nieuwdorp M
Diabetes Obes Metab; 2012 Feb; 14(2):112-20. PubMed ID: 21812894
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance?
Esteve E; Ricart W; Fernández-Real JM
Curr Opin Clin Nutr Metab Care; 2011 Sep; 14(5):483-90. PubMed ID: 21681087
[TBL] [Abstract][Full Text] [Related]
4. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
5. [Physiological patterns of intestinal microbiota. The role of dysbacteriosis in obesity, insulin resistance, diabetes and metabolic syndrome].
Halmos T; Suba I
Orv Hetil; 2016 Jan; 157(1):13-22. PubMed ID: 26708682
[TBL] [Abstract][Full Text] [Related]
6. Gut Microbiota as a Therapeutic Target for Metabolic Disorders.
Okubo H; Nakatsu Y; Kushiyama A; Yamamotoya T; Matsunaga Y; Inoue MK; Fujishiro M; Sakoda H; Ohno H; Yoneda M; Ono H; Asano T
Curr Med Chem; 2018; 25(9):984-1001. PubMed ID: 28990516
[TBL] [Abstract][Full Text] [Related]
7. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity.
Vrieze A; Out C; Fuentes S; Jonker L; Reuling I; Kootte RS; van Nood E; Holleman F; Knaapen M; Romijn JA; Soeters MR; Blaak EE; Dallinga-Thie GM; Reijnders D; Ackermans MT; Serlie MJ; Knop FK; Holst JJ; van der Ley C; Kema IP; Zoetendal EG; de Vos WM; Hoekstra JB; Stroes ES; Groen AK; Nieuwdorp M
J Hepatol; 2014 Apr; 60(4):824-31. PubMed ID: 24316517
[TBL] [Abstract][Full Text] [Related]
8. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
[TBL] [Abstract][Full Text] [Related]
9. The intricate association between gut microbiota and development of type 1, type 2 and type 3 diabetes.
Bekkering P; Jafri I; van Overveld FJ; Rijkers GT
Expert Rev Clin Immunol; 2013 Nov; 9(11):1031-41. PubMed ID: 24138599
[TBL] [Abstract][Full Text] [Related]
10. Gut microbiota and host metabolism in liver cirrhosis.
Usami M; Miyoshi M; Yamashita H
World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
Han R; Ma J; Li H
Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
[TBL] [Abstract][Full Text] [Related]
12. Targeting gut microbiota as a possible therapy for diabetes.
He C; Shan Y; Song W
Nutr Res; 2015 May; 35(5):361-7. PubMed ID: 25818484
[TBL] [Abstract][Full Text] [Related]
13. Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes?
Diamant M; Blaak EE; de Vos WM
Obes Rev; 2011 Apr; 12(4):272-81. PubMed ID: 20804522
[TBL] [Abstract][Full Text] [Related]
14. Probiotics, prebiotics, synbiotics and insulin sensitivity.
Kim YA; Keogh JB; Clifton PM
Nutr Res Rev; 2018 Jun; 31(1):35-51. PubMed ID: 29037268
[TBL] [Abstract][Full Text] [Related]
15. Obesity, fatty liver disease and intestinal microbiota.
Arslan N
World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
[TBL] [Abstract][Full Text] [Related]
16. The influence of probiotics on bile acids in diseases and aging.
Sivamaruthi BS; Fern LA; Rashidah Pg Hj Ismail DSN; Chaiyasut C
Biomed Pharmacother; 2020 Aug; 128():110310. PubMed ID: 32504921
[TBL] [Abstract][Full Text] [Related]
17. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
[TBL] [Abstract][Full Text] [Related]
18. Gut microbiota and metabolic syndrome.
Festi D; Schiumerini R; Eusebi LH; Marasco G; Taddia M; Colecchia A
World J Gastroenterol; 2014 Nov; 20(43):16079-94. PubMed ID: 25473159
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?
Li DY; Yang M; Edwards S; Ye SQ
JPEN J Parenter Enteral Nutr; 2013 Nov; 37(6):787-93. PubMed ID: 23538296
[TBL] [Abstract][Full Text] [Related]
20. [The role of gut microbiota in the pathogenesis of obesity and diabetes].
Stachowicz N; Kiersztan A
Postepy Hig Med Dosw (Online); 2013 Apr; 67():288-303. PubMed ID: 23619228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
